Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAHCT AV-101 in pulmonary arterial hypertension
2021-001910-13Phase 2Active
- Sponsor
- Aerovate Therapeutics
- Start
- Dec 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing AV-101 with Placebo (2 arms). Primary endpoints: Change from baseline in pulmonary vascular resistance, Safety and tolerability of AV-101 and 1 more. Started Dec 2021; status: active.
02
Drugs
4-chlorokynurenine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2021-001910-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001910-13.